Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP18 | Q9UMW8 | 2/20 | 0.67 |
| ▸ | UCHL5 | Q9Y5K5 | 2/20 | 0.67 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | IKBKB | O14920 | 1/20 | 0.59 |
| ▸ | CASP3 | P42574 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.55 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.55 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.55 |
| ▸ | METAP1 | P53582 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 3/20 | 0.51 |
| ▸ | APP | P05067 | 3/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14797848 | 1.00 | USP18 (0.67) | USP18UCHL5HSP90AA1USP2MEN1 | |
| SCHEMBL17693765 | 0.87 | USP18 (0.53) | USP18UCHL5HSP90AA1USP2MEN1 | |
| SCHEMBL14880647 | 0.83 | USP18 (0.52) | USP18UCHL5HSP90AA1USP2MEN1 | |
| SCHEMBL14880648 | 0.83 | USP18 (0.52) | USP18UCHL5HSP90AA1USP2MEN1 | |
| SCHEMBL9619486 | 0.83 | USP18 (0.67) | USP18UCHL5HSP90AA1USP2CASP3 | |
| SCHEMBL9619484 | 0.83 | USP18 (0.67) | USP18UCHL5HSP90AA1USP2CASP3 | |
| SCHEMBL26107651 | 0.82 | METAP1 (0.51) | USP18UCHL5HSP90AA1USP2KMT2A | |
| SCHEMBL28829498 | 0.81 | MAPT (0.64) | HSP90AA1MEN1KMT2AIKBKBMAPT | |
| SCHEMBL14880394 | 0.80 | CYP1A2 (0.56) | USP18UCHL5HSP90AA1USP2MEN1 | |
| SCHEMBL14880392 | 0.80 | CYP1A2 (0.56) | USP18UCHL5HSP90AA1USP2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4539841-A2 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | claimed |
| EP-4442093-A1 | COMPOUNDS HAVING FLUORENE STRUCTURES | Merck Patent GmbH (DE) | 2024-10-09 | — | — | EP | claimed |
| WO-2023244996-A2 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | claimed |
| WO-2023099543-A1 | COMPOUNDS HAVING FLUORENE STRUCTURES | MERCK PATENT GMBH (DE) | 2023-06-08 | — | — | WO | claimed |
| US-20220111019-A1 | BRCA1 MODULATING COMPOUNDS, FORMULATIONS THEREOF, AND USES THEREOF | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. | 2022-04-14 | — | — | US | claimed |
| US-12595271-B2 | Aromatic compounds for organic electroluminescent devices | UDC IRELAND LIMITED (IE) | 2026-04-07 | — | — | US | disclosed |
| EP-4682156-A1 | LINKER AND DRUG CONJUGATE USING SAME, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | Shanghai Affinity Biopharmaceutical Co., Ltd. (CN) | 2026-01-21 | — | — | EP | disclosed |
| EP-4633640-A1 | HALOGENATED SALICYLANILIDE DERIVATIVES AS USP8 INHIBITORS FOR THERAPEUTIC USES | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2025-10-22 | — | — | EP | disclosed |
| EP-4587050-A1 | ANTIBODIES AND METHOD OF USE FOR P. GINGIVALIS | Shi, Xiaoju (GB) | 2025-07-23 | — | — | EP | disclosed |
| CN-119932068-A | Genetically engineered bacterium for producing rosmarinic acid and construction method and application thereof | 天津大学浙江研究院(绍兴) | 2025-05-06 | — | — | CN | disclosed |
| EP-4539841-A2 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-118995490-B | Pinus massoniana red spot antagonistic bacterium AH2-38 and application thereof | 南京林业大学 | 2025-03-18 | — | — | CN | disclosed |
| US-20230045142-A1 | SMALL MOLECULE RPN13 INHIBITORS WITH ANTITUMOR PROPERTIES | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-02-09 | — | — | US | disclosed |
| EP-4110522-A1 | DIBORIDE MICROPATTERNED SURFACES FOR CELL CULTURE | University of Houston System (US) | 2023-01-04 | — | — | EP | disclosed |
| CN-115443191-A | Diboride micropatterned surfaces for cell culture | 休斯敦大学体系 | 2022-12-06 | — | — | CN | disclosed |
| US-20220111019-A1 | BRCA1 MODULATING COMPOUNDS, FORMULATIONS THEREOF, AND USES THEREOF | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. | 2022-04-14 | — | — | US | disclosed |
| US-20210283139-A1 | BIFUNCTIONAL MOLECULES FOR TARGETING UCHL5 | AMPHISTA THERAPEUTICS LIMITED (GB) | 2021-09-16 | — | — | US | disclosed |
| US-20200399220-A1 | 3,5-DIARYLIDENYL-N-SUBSTITUTED-PIPERID-4-ONE-DERIVED INHIBITORS OF STAT3 PATHWAY ACTIVITY AND USES THEREOF | KIAKOS KONSTANTINOS (AT) | 2020-12-24 | — | — | US | disclosed |
| US-20130079370-A1 | Method for the Inhibition of Deubiquitinating Activity | VIVOLUX AB (SE) | 2013-03-28 | — | — | US | disclosed |
| US-20130079370-A1 | Method for the Inhibition of Deubiquitinating Activity | VIVOLUX AB (SE) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079370-A1 | Method for the Inhibition of Deubiquitinating Activity | USP25, USP5, API5 | USP18 8/4885UCHL5 18/4885HSP90AA1 962/4885 |
| US-20210283139-A1 | BIFUNCTIONAL MOLECULES FOR TARGETING UCHL5 | UCHL5, UCHL3, UCHL1 | USP18 40/4885UCHL5 1/4885HSP90AA1 1847/4885 |
| US-12595271-B2 | Aromatic compounds for organic electroluminescent devices | SCO2, NR2C2, AR | USP18 4784/4885UCHL5 4712/4885HSP90AA1 4278/4885 |
| US-20200399220-A1 | 3,5-DIARYLIDENYL-N-SUBSTITUTED-PIPERID-4-ONE-DERIVED INHIBITORS OF STAT3 PATHWAY ACTIVITY AND USES THEREOF | STAT3, JAK2, STAT6 | USP18 3651/4885UCHL5 3363/4885HSP90AA1 1134/4885 |
| US-20230045142-A1 | SMALL MOLECULE RPN13 INHIBITORS WITH ANTITUMOR PROPERTIES | MRPS23, RPP30, RPS19 | USP18 361/4885UCHL5 1631/4885HSP90AA1 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.